Hemgenix (Etranacogene Dezaparvovec)

Hemgenix is indicated for the long‑term management of hemophilia B in patients who are eligible for gene‑therapy treatment.

• Delivers a functional copy of the factor IX gene to hepatocytes, enabling sustained endogenous production of factor IX.
• Reduces the frequency and severity of spontaneous and traumatic bleeding episodes in individuals with severe or moderately severe hemophilia B.
• May decrease or eliminate the need for regular factor IX replacement therapy or prophylactic infusions.
• Administered as a single intravenous infusion, typically performed in a specialized treatment center.
• Intended for patients who have limited response to conventional factor replacement or who seek a durable therapeutic option.

The safety profile of Hemgenix includes both common and serious adverse events observed in clinical studies.

Common

• Transient elevation of liver enzymes (ALT, AST) that usually resolves with monitoring.
• Mild to moderate infusion‑related reactions such as fever, chills, or headache.
• Fatigue or general malaise occurring within the first few weeks after administration.
• Nausea or mild gastrointestinal discomfort reported by some patients.

Serious

• Persistent or severe hepatic inflammation requiring medical intervention.
• Development of an immune response to the viral vector leading to reduced efficacy.
• Thrombotic events or clotting disorders, although rare, have been reported.

Clinicians should consider several precautions and warnings before prescribing Hemgenix to ensure patient safety.

• Baseline liver function tests are required, and patients should be monitored regularly for hepatic enzyme elevations.
• Patients with active hepatitis B, C, or other significant liver disease are generally excluded from treatment.
• The long‑term durability of factor IX expression is still being evaluated; ongoing follow‑up is recommended.
• Use of immunosuppressive therapy may be needed to manage vector‑related immune reactions.
• Women who are pregnant or may become pregnant should avoid exposure, as safety data are lacking.
• Concomitant use of anticoagulants may increase bleeding risk and should be assessed carefully.

Hemgenix may interact with other medications or biologics; understanding these interactions helps optimize therapy.

Avoid

• Concurrent administration of high‑dose corticosteroids that could suppress the intended immune response to the vector.
• Use of other gene‑therapy products targeting the liver, which may increase risk of hepatic toxicity.

Use with caution

• Anticoagulants or antiplatelet agents, as changes in coagulation status may affect bleeding assessments.
• Immunosuppressive agents, which could alter the efficacy of the viral vector.
• Hepatotoxic drugs, including certain antibiotics and antifungals, due to potential additive liver stress.
• Live vaccines, because immune modulation may affect vaccine response.